Lilly, Novo GLP-1 Pricing Plans Clear Runway For Future Competitors

By /

While the TrumpRx deals only cover Lilly and Novo for now, the agreements are good for any cardiometabolic biotechs waiting in the wings, according to a new 2026 preview report from PitchBook.

Scroll to Top